Health Care Delivery

A child with profound genetic hearing loss was dosed with the investigational otoferlin gene therapy (DB-OTO), becoming the first patient dosed in a phase 1/2 trial evaluating the treatment, and experienced improved auditory response at week 6 with no concerning safety signals.

Sara Horst MD, MPH, FACG, discusses recent improvements she helped make to the Vanderbilt University Medical Center's (VUMC) digital health systems and what changes she plans to help implement in the future.

The annual Patient-Centered Oncology Care® (PCOC) meeting returns to Nashville, Tennessee, on November 7-8, bringing oncology stakeholders together for 2 days of discussions and presentations on the rapidly changing oncology care landscape.

“Our findings further reinforce that place is important and that the social, economic, and health care equity context is key to minimizing health care expenditure disparities for Black adults in the US," investigators explain.

Two posters presented at Kidney Week 2023 evaluated the global state of chronic kidney disease (CKD) and shed light on delays in CKD diagnoses in the United States.

Presenters at the American Society of Nephrology's Kidney Week 2023 discussed the past, present, and future of pediatric chronic kidney disease, as well as explored the obstacles and solutions for effective trial designs.

Sickle cell disease (SCD) has known complications that include organ damage and failure, rhabdomyolysis, glaucoma, splenic sequestration, and vaso-occlusive crises. At present, the only potential cure is a bone marrow transplant, but it can be difficult to find a donor and there is a high rejection risk.

Amy Laughlin, MD, MSHP, of Orlando Health gave a preview of the topic she is presenting on at today's American Journal of Managed Care®’s Institute for Value-Based Medicine® event in New York City.

The American Cancer Society expanded eligibility for lung cancer screening; experts advised patients to do their research before choosing a plan from the Affordable Care Act’s insurance marketplaces; Republican-led states partnering with rideshare companies for medical appointment rides.

After implementing a multidisciplinary surgical approach, researchers found that use of the new approach, residual disease, and age were all independent predictors of overall and progression-free survival for patients with ovarian cancer.

A difference-in-differences analysis of health care claims data evaluated excess health care costs in the 12 months following COVID-19 diagnosis among the general and older adult populations.

The prevalence of obesity in the Sutter Health system between 2015 and 2020 was 35%. Differences by race/ethnicity, health insurance, smoking status, and comorbidities were examined.

The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.

Anshul Mangal, biotech entrepreneur, attorney, CEO, and founder of Project Farma, discusses how supply chain disruptions and the current cancer drug shortage are affecting patients.

Results from the OPEB-01/APGOT-OV4 trial highlight the potential benefits of using olaparib, pembrolizumab, and bevacizumab as a triplet maintenance therapy for patients who have responded to chemotherapy after experiencing platinum-sensitive recurrence in ovarian cancer.

Insurance status is known to be associated with health care access and outcomes, and a recent study found that maternal private insurance is associated with a lower infant mortality rate compared with public Medicaid insurance in the United States.

Providing at-home hemoglobin A1c test kits increases testing rates and facilitates hemoglobin A1c reduction over time among members of a large commercial health plan with diabetes.

Data from the SPHERE registry revealed racial and ethnic discrepancies in disease severity, comorbidities, and outcomes experienced by patients with pulmonary arterial hypertension (PAH) receiving selexipag.

Democratic senators urge private insurers fully cover Opill, an OTC contraceptive pill; providers pursue lawsuit against Arizona's abortion rule; a quarter of US medical students contemplate leaving their studies.

Federal actuaries have projected what they believe to be health care spending through 2030-2031 in 9 important areas.

Patients with a history of retinal artery occlusions were found to have an increased risk of myocardial infarction and death compared with patients who had cataracts.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed cost savings that occurred so far from their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health and also noted those they predict to occur as the program continues.

Investigators hope that ongoing research and addressing disparities can improve equitable access to asthma treatments for all pediatric patients.

Pharmacy workers embark on a multiday strike; Fathers are taking paid family leave to bond with their newborns; the FDA is set to evaluate a pioneering gene therapy for sickle cell disease (SCD).

Adults with osteoarthritis who took part in a digital musculoskeletal program had lower rates of knee and hip arthroplasty at 12 months vs those using traditional care.

Kristine Slam, MD, FACP, discusses the importance of genetic testing in male patients with breast cancer and why it’s important that all patients with breast cancer advocate for themselves.

At ERS International Congress 2023, new data related to use of sotatercept offered providers additional insight into the effects of the agent in people with pulmonary arterial hypertension (PAH).

The study identified practical instruments for monitoring physical function in people with hemophilia by pinpointing 11 potential markers and establishing performance-based tests for 5 of these activities.

A study of patients with relapsed or refractory (R/R) multiple myeloma who received ixazomib-based therapy in real-world settings found the treatment effective and tolerable in clinical practice.

Results showed higher-exposure dupilumab met the study’s primary endpoint for peak esophageal intraepithelial count ≤6 eos/high-power field.